Amprenavir

Generic Name: Amprenavir

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₅N_₃O_₆S

CAS Number: 161814-49-9

Unique Ingredient Identifier: 5S0W860XNR

Background: Amprenavir is a protease inhibitor used to treat HIV infection.

Indication: 用于高效抗逆转录病毒疗法（HAART）的组成药物。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Phase 4

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 300

Registration Number: NCT00005017

Locations: 🇺🇸
Jaime Hernandez, Research Triangle Park, North Carolina, United States

Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment

Not Applicable

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gathe, Joseph, M.D.

Registration Number: NCT00006591

Locations: 🇺🇸
Gathe, Joseph, M.D., Houston, Texas, United States

A Comparison of 141W94 and Indinavir in HIV-Infected Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 460

Registration Number: NCT00002202

Locations: 🇺🇸
Community Research Initiative on AIDS, New York, New York, United States
🇺🇸
Whitman Walker Clinic Inc, Washington, District of Columbia, United States
🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States

and more 21 locations

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 80

Registration Number: NCT00002440

Locations: 🇺🇸
Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit, New Haven, Connecticut, United States
🇺🇸
Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
🇺🇸
UCSD Treatment Ctr, San Diego, California, United States

and more 5 locations

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002217

Locations: 🇺🇸
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 25

Registration Number: NCT00002419

Locations: 🇺🇸
Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States

and more 2 locations

A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 290

Registration Number: NCT00002195

Locations: 🇺🇸
Chicago Ctr for Clinical Research, Chicago, Illinois, United States
🇺🇸
Dr Bruce Rashbaum, Washington, District of Columbia, United States
🇺🇸
Community Research Initiative of South Florida, Coral Gables, Florida, United States

and more 6 locations

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 80

Registration Number: NCT00002213

Locations: 🇺🇸
Niaid / Nih, Bethesda, Maryland, United States
🇺🇸
Northwestern Univ Med School AIDS Treatment Unit, Chicago, Illinois, United States
🇺🇸
Univ Int Med Assoc Inc / Holmes Hosp / U of Cincinnati, Cincinnati, Ohio, United States

and more 6 locations

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 60

Registration Number: NCT00002183

Locations: 🇺🇸
UCSD, San Diego, California, United States
🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

A Study of Amprenavir in HIV-Infected Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002405

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy